Nicholas Butowski

MD

Neuro-oncologist
Avid football – also known as soccer – fan

Dr. Nicholas Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a researcher at the Brain Tumor Center.

In his research, Butowski focuses on developing treatments for primary brain tumors as well as methods to ensure good quality of life for patients and to assist them in recovering from or coping with brain injury.

Butowski earned his medical degree at the University of Illinois at Chicago. He completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

  • Education

    University of Illinois College of Medicine, 1999

  • Residencies

    UCSF Medical Center, Neurology, 2003

  • Fellowships

    UCSF Medical Center, Neuro-oncology, 2004

  • Academic Title

    Professor

Compassion is not a virtue; it is a commitment.

Conditions I specialize in

Clinics I work with

View map

Brain Tumor Center

400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143

(415) 353-2966
M-F, 8 a.m. - 5 p.m.

My reviews

5.0

Overall Experience
115 Reviews
I would not want to work with anyone other than Dr Butowski. I completely trust that he has my best interest in mind when making treatment recommendations.
Explained things in a way that was easy to understand
114 Reviews
Did the doctor pay attention to your concerns
114 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
108 Reviews
Knew the important information about your medical history
113 Reviews
The provider showed respect for what you had to say
114 Reviews
The provider spent enough time with me
111 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Number of patients who experienced a treatment-related adverse event

Recruiting

Decorative Caduceus

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Time from Gliadel placement to death

Recruiting

Decorative Caduceus

PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma

Objective response rate (comprised of patients meeting an objective radiographic response or ORR): Patients achieving a CR or PR. DOR: Time from first ORR observed (once confirmed) until PD first observed (once confirmed) or deat...

Recruiting

Decorative Caduceus

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Best overall response rate by RANO

Recruiting

Decorative Caduceus

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolom...

Assessment of overall survival. With standard treatment, the median survival of Grade IV patients is expected to be 14.6 months, and the median survival of Grade III is approximately 36 months. Given that we anticipate that approx...

Recruiting

Decorative Caduceus

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade...

Incidence and severity of treatment-related adverse events, using standard criteria as well as close clinical follow-up as would be performed normally in this group of participants following vaccinations. All reported or observed ...

Recruiting

Decorative Caduceus

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA...

Recruiting

Contact me

Providers on my team

Share